BPOM: Tirzepatide Expands Diabetes and Weight Management Therapy
The Indonesian Food and Drug Authority (BPOM) stated that the arrival of products containing the active ingredient tirzepatide, provided by PT Anugerah Pharmindo Lestari, is expected to expand treatment options for patients, particularly in the management of type 2 diabetes mellitus and body weight.
Head of BPOM, Taruna Ikrar, noted that both conditions pose significant challenges to global health, given their increasing prevalence and widespread impact on public quality of life. Therefore, serious attention is required for their management.
“BPOM remains committed to implementing various breakthroughs in an effort to increase the availability of new, innovative medicines in Indonesia,” he said in Jakarta on Sunday.
He explained that type 2 diabetes mellitus is a non-communicable disease with high prevalence. Data from the International Diabetes Federation (IDF) Diabetes Atlas (2025) shows that approximately 11.1 per cent of the world’s adult population lives with diabetes, with 4 out of 10 people unaware they have the disease.
The rising prevalence of obesity is an equally important health challenge. Global data indicates that the number of individuals who are overweight or obese continues to increase, including in Indonesia.
Citing data from the 2023 Indonesian Health Survey (SKI), the prevalence of obesity among adults aged 18 and over has shown an increase in recent years, from 21.8 per cent in 2018 to 23.4 per cent in 2023. This condition contributes to the increased risk of chronic diseases and impacts the burden on the healthcare system and national productivity.
“This situation underscores the importance of a holistic approach in managing metabolic diseases, which includes prevention, early detection, lifestyle changes, and the availability of effective, evidence-based therapies,” he said.
He explained that tirzepatide is an active ingredient that works through a mechanism similar to hormones naturally released by the body, namely glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). These hormones are produced in the intestines and bind to several specific receptors in the body, including in the pancreas and the brain.
As with the function of these two hormones, tirzepatide works within the body by increasing insulin secretion, suppressing glucagon hormones, and increasing insulin sensitivity, which helps regulate blood sugar levels. Additionally, tirzepatide slows gastric emptying, making it useful for weight management.
“The presence of tirzepatide as an innovative therapy is expected to expand treatment options for patients, particularly in the management of type 2 diabetes mellitus and weight,” said Taruna.
The therapeutic innovation of tirzepatide in treating type 2 diabetes and weight management is part of the effort to improve the quality of healthcare services and provide tangible benefits to the community.
In addition to tirzepatide, the authority has also issued marketing authorisations for similar drugs with similar indications, namely semaglutide and liraglutide.
BPOM is committed to ensuring that every medicinal product circulating in Indonesia, including tirzepatised, has undergone a rigorous evaluation process in accordance with international standards. Thus, the safety, efficacy, and quality of the products remain guaranteed.
“After obtaining marketing authorisation, drug safety continues to be monitored through pharmacovigilance as part of post-marketing surveillance,” he said.
The launch of tirzepatide further completes the range of therapeutic options for patients in Indonesia and is expected to support the overall improvement of public health.
Taruna emphasised the importance of collaboration between regulators, the pharmaceutical industry, and healthcare professionals in supporting the accelerated access to innovative medicines to ensure they are tangibly available and utilised within the Indonesian healthcare system.
Source: jawawa.id (https://jawawa.id/newsitem/bpom-tirzepatide-expands-diabetes-and-weight-management-therapy-1783234333)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5636068/bpom-tirzepatide-perluas-terapi-diabetes-manajemen-berat-badan), translated from Indonesian